HROW vs. ERAS, MREO, RANI, ADCT, AMRN, TERN, ANRO, NATR, CRBP, and MRSN
Should you be buying Harrow stock or one of its competitors? The main competitors of Harrow include Erasca (ERAS), Mereo BioPharma Group (MREO), Rani Therapeutics (RANI), ADC Therapeutics (ADCT), Amarin (AMRN), Terns Pharmaceuticals (TERN), Alto Neuroscience (ANRO), Nature's Sunshine Products (NATR), Corbus Pharmaceuticals (CRBP), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical preparations" industry.
Erasca (NASDAQ:ERAS) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership.
Erasca has a net margin of 0.00% compared to Erasca's net margin of -18.75%. Erasca's return on equity of -29.48% beat Harrow's return on equity.
67.8% of Erasca shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 29.8% of Erasca shares are owned by insiders. Comparatively, 13.6% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Harrow has higher revenue and earnings than Erasca. Harrow is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.
Erasca has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500.
Harrow received 63 more outperform votes than Erasca when rated by MarketBeat users. However, 61.54% of users gave Erasca an outperform vote while only 55.63% of users gave Harrow an outperform vote.
Erasca presently has a consensus target price of $7.83, indicating a potential upside of 320.02%. Harrow has a consensus target price of $28.13, indicating a potential upside of 75.50%. Given Harrow's higher possible upside, research analysts plainly believe Erasca is more favorable than Harrow.
In the previous week, Harrow had 1 more articles in the media than Erasca. MarketBeat recorded 11 mentions for Harrow and 10 mentions for Erasca. Erasca's average media sentiment score of -0.15 beat Harrow's score of -0.27 indicating that Harrow is being referred to more favorably in the news media.
Summary
Harrow beats Erasca on 10 of the 17 factors compared between the two stocks.
Get Harrow News Delivered to You Automatically
Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
